OSLO, Norway, Oct. 26, 2018 /PRNewswire/ --
Targovax ASA (OSE: TRVX, Targovax), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, will announce its third quarter 2018 results on Thursday, 1 November 2018 at 07:00 CET.
The results report, and the presentation will be available at www.targovax.com in the investors section from 07:00 CET.
Øystein Soug, Chief Executive Officer of Targovax, will host an online presentation for investors, analysts and the press at 08:45 CET. The presentation can be followed here, or at: https://www.facebook.com/AXExposure/videos/279295392691286/
For an elaborate presentation of the Targovax strategy, please visit targovax.com for a replay of the 15 October 2018 Capital Markets Day.
For further information, please contact:
Renate Birkeli, Investor Relations
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
This information was brought to you by Cision http://news.cision.com